Conference call planned for later in Q4 2024 to provide updates on NurOwn® program NEW YORK, Nov. 14, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: ...

Fintel reports that on November 14, 2024, JP Morgan initiated coverage of Blueprint Medicines (NasdaqGS:BPMC) with a ...

JP Morgan initiated coverage on Blueprint Medicines Corporation (NASDAQ:BPMC), a biotech company focused on modulating immune ...

BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced its intent to change the Comp ...

JPMorgan initiated coverage of Blueprint Medicines (BPMC) with an Overweight rating and $126 price target Blueprint is a biotech company ...

For the past three years, biotechs and pharmas have renamed, rebranded and more in a bid to refresh their corporate appeal. ...

Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase 1/2 clinical trial highlighting ...

Researchers at Uppsala University and KTH Royal Institute of Technology have developed a new form of precision medicine, an antibody, with the potential to treat several types of cancer.

The life science group Sartorius has released its second edition of the “High-Throughput Screening (HTS) by Cytometry” handbook, tailored to support new and experienced researchers who use flow ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the pivotal Phase 3 study design following successful alignment with the U.S. Food and Drug Administration (FDA) on ION582, an ...